Vertex expands label for Casgevy to young children with sickle cell disease

The US FDA has supplementally approved Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β-thalassemia (TDT) — marking the first gene therapy approved for young children with SCD. Vertex Pharmaceuticals received the approval, which extends a label previously restricted to patients aged 12 years and older, and was processed in 53 days under the FDA Commissioner’s National Priority Voucher pilot program.

Casgevy is a one-time autologous cell therapy administered as a single intravenous infusion following full myeloablative conditioning. It uses CRISPR/Cas9 genome editing to disrupt the BCL11A erythroid enhancer in the patient’s own hematopoietic stem cells, reactivating fetal hemoglobin (HbF) production — the scientific basis for which was recently recognized with a Breakthrough Prize. Elevated HbF prevents red blood cells from adopting the sickle morphology that drives VOCs in SCD and reduces transfusion dependence in TDT.

The supplemental approval was supported by two pediatric cohort studies in patients aged 5 to under 12 years. In the SCD trial (11 patients), all eight efficacy-evaluable patients achieved the primary endpoint of VF12 — defined as freedom from protocol-defined severe VOCs for at least 12 consecutive months within 24 months post-infusion. In the TDT trial (15 patients), eight of nine efficacy-evaluable patients achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months. The FDA extended the approved age range to 2 years based on extrapolation from product characteristics and these pediatric data. The most common adverse reactions were mucositis and febrile neutropenia; prescribing information carries warnings for neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and off-target genome editing risk.

The AllSci BriefSystematic R&D and deal news. Daily.

Within the gene therapy landscape, Casgevy’s closest approved competitor in SCD is bluebird bio’s Lyfgenia (lovotibeglogene autotemcel), which uses lentiviral vector-based gene addition rather than CRISPR editing and is currently indicated for patients aged 12 years and older — meaning Casgevy now holds a younger age label in SCD. Editas Medicine’s EDIT-301, an ex vivo CRISPR-edited HSC therapy in Phase I/II for both SCD and TDT, remains an earlier-stage competitor in the same modality space.

The age extension is clinically meaningful beyond regulatory labeling. Pediatric SCD causes progressive end-organ damage — splenic sequestration, stroke risk, and neurocognitive effects — that accumulates before adolescence, making earlier intervention a plausible strategy for reducing long-term morbidity. Whether the one-time treatment durability observed in older cohorts holds across younger patients treated at earlier disease stages will require longer follow-up from the ongoing trials.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/